Bristol Myers Squibb is purchasing an Nvidia DGX SuperPOD built on the chipmaker's Vera Rubin architecture to support artificial intelligence use across its drug discovery and development operations. The pharmaceutical company said it will be the first life sciences group to acquire a DGX SuperPOD based on Vera Rubin.
Nvidia introduced the Vera Rubin architecture earlier this year as a more efficient and scalable solution for AI-driven research. The DGX SuperPOD is a high-performance computing platform that enables researchers to process complex data sets in real-time, accelerating drug discovery and development timelines.
The acquisition comes as Nvidia continues to push the boundaries of artificial intelligence with its cutting-edge technology. The Vera Rubin architecture is expected to bring significant improvements in AI performance, making it an attractive solution for pharmaceutical companies like Bristol Myers Squibb that are investing heavily in this field.